Atara Biotherapeutics Inc
NASDAQ:ATRA
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.6100
  • TODAY'S CHANGE (%)
    0.0064 (1.0603%)
  • Bid / Lots
    0.6000/ 150
  • Ask / Lots
    0.6375/ 50
  • Open / Previous Close
    0.6000 / 0.6036
  • Day Range
    0.5856
    0.6349
  • 52 Week Range
    0.1986
    2.5350
  • Volume
    1,824,862

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ATRA
Atara Biotherapeutics Inc
73.5M
-0.3x
---
IKNA
Ikena Oncology Inc
69.0M
-0.9x
---
JAGX
Jaguar Health Inc
75.8M
-0.2x
---
CRIS
Curis Inc
69.6M
-1.4x
---
LVTX
LAVA Therapeutics NV
69.4M
-1.7x
---
CLGN
Collplant Biotechnologies Ltd
72.6M
-10.0x
---
As of 2024-05-19

Company Information

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

Contact Information

Headquarters
2380 Conejo Spectrum St, Suite 200THOUSAND OAKS, CA, United States 91320
Phone
805-623-4244
Fax
302-636-5454

Executives

Independent Chairman of the Board
Carol Gallagher
President, Chief Executive Officer, Director
Pascal Touchon
Chief Financial Officer, Senior Vice President, Investor Relations and Finance
Eric Hyllengren
Executive Vice President, Chief Legal Officer
K. Amar Murugan
Independent Director
Matthew Fust

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$73.5M
Revenue (TTM)
$34.7M
Shares Outstanding
120.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.55
EPS
$-2.12
Book Value
$-0.93
P/E Ratio
-0.3x
Price/Sales (TTM)
2.1
Price/Cash Flow (TTM)
---
Operating Margin
-669.19%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.